Last reviewed · How we verify
Osteo D (SECALCIFEROL)
Osteo D (generic name: SECALCIFEROL) is a secalciferol drug. It is currently in Phase 2 development.
Secalciferol works by binding to vitamin D receptors in the body, triggering a response that increases calcium and phosphate levels.
Osteo D (Secalciferol) is a small molecule drug in the secalciferol class, used to treat vitamin D deficiency. It works by stimulating the production of calcium and phosphate in the body, which is essential for bone growth and maintenance. The commercial status of Osteo D is unknown, and it is not clear if it is patented or generic. Key safety considerations include potential interactions with other medications and monitoring of calcium levels. Secalciferol is a form of vitamin D that is naturally produced in the skin upon exposure to sunlight.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SECALCIFEROL |
|---|---|
| Drug class | secalciferol |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | Phase 2 |
Mechanism of action
Imagine your body has a special lock that only opens with a specific key. Vitamin D receptors are like those locks, and secalciferol is the key that fits perfectly. When secalciferol binds to these receptors, it sends a signal to the body to increase the production of calcium and phosphate, which are essential for building and maintaining strong bones.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Osteo D CI brief — competitive landscape report
- Osteo D updates RSS · CI watch RSS
Frequently asked questions about Osteo D
What is Osteo D?
How does Osteo D work?
What is the generic name of Osteo D?
What drug class is Osteo D in?
What development phase is Osteo D in?
Related
- Drug class: All secalciferol drugs
- Therapeutic area: All drugs in Bone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing